MiMedx Group

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MiMedx Group reports robust Q4 performance and eyes growth opportunities

MiMedx Group's Q4 2022 earnings call highlighted strong performance, strategic focus on growth objectives, and addressing challenges in reimbursement and regulatory landscape. The company's emphasis on technology, personnel, and growth opportunities positions it for continued success.

MiMedx Group reports robust Q1 performance and eyes international growth

MiMedx Group's Q1 2023 performance reflects a balanced focus on profitability and revenue growth, driven by new product launches and strategic initiatives.
Despite challenges such as product launch delays and market dynamics, the company remains optimistic about growth opportunities in Japan and beyond.
With a strong emphasis on efficiency, innovation, and market expansion, MiMedx Group is positioned for continued growth and success in the evolving healthcare landscape.

MiMedx Group excels in Q2, eyes growth amid challenges

MiMedx Group's Q2 2023 performance reflects strong financial results, operational efficiency, and a strategic shift towards wound and surgical markets.
While facing challenges related to supply chain disruptions and regulatory compliance, the company is well-positioned to capitalize on growth opportunities and drive innovation.
Investors can be optimistic about MiMedx Group's financial outlook, legal standing, and commitment to market expansion through product development and strategic partnerships.

MiMedx Group reports robust Q3 earnings, eyes Japanese market growth

MiMedx Group's Q3 performance reflects strong financial results, strategic product launches, and growth in key markets despite challenges.
The company's focus on operational efficiency, expansion in the Japanese market, and product portfolio diversification position it well for future success.
While facing challenges from Medicare LCD changes and potential cannibalization, MiMedx remains optimistic about growth opportunities and aims for continued momentum.

MiMedx Group excels in Q4, poised for sustained growth

MiMedx Group's Q4 performance exceeded expectations with revenue growth and improved margins.
The company's strategic focus on growth drivers and financial discipline sets a strong foundation for 2024.
While facing challenges in certain areas, MiMedx is well-positioned to capitalize on opportunities for expansion.
Overall, MiMedx's financial health and growth prospects indicate a positive outlook for the future.

MiMedx Group reports robust Q1 earnings amidst strategic growth plans

MiMedx Group (MDXG) had a strong start in Q1 2024, showcasing financial strength and strategic focus on growth.
The company faces challenges from potential market disruptions and cost pressures but remains optimistic about opportunities.
Key initiatives include product innovation, market expansion, and navigating reimbursement landscape changes.

MiMedx Group reports solid Q2 earnings, navigates reimbursement challenges

MiMedx Group's Q2 performance reflects steady growth, strong financial health, and a strategic focus on innovation and customer relationships.
While facing challenges in reimbursement dynamics and regulatory uncertainties, the company remains resilient and poised for growth opportunities in the market.
With a solid product portfolio and emphasis on operational efficiency, MiMedx Group is well-positioned to navigate challenges and capitalize on future market prospects.

MiMedx Group reports solid Q3 growth amid reimbursement challenges

MiMedx Group's Q3 performance reflects resilience and growth amidst challenges, with a focus on innovation and customer-centric strategies for future success.
The company's financial stability, positive market reception of HELIOGEN, and increasing platform adoption position it well for capitalizing on opportunities ahead.
While facing challenges in reimbursement dynamics and operational efficiency, MiMedx Group remains optimistic about future corrections and growth prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

First Quarter Net Sales of $71.7 Million Reflect an Increase of 21.7% Over the Prior Year Period

MIMEDX Announces First Quarter 2023 Operating and Financial Results

MARIETTA, Ga., April 18, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it will report operating and financial results for the first quarter ended March 31, 2023 after the market close on Tuesday, May 2, 2023. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 5:00 p.m. Eastern Time on the same day.

MIMEDX to Host First Quarter 2023 Operating and Financial Results Conference Call on May 2

Executive Search Underway Executive Search Underway

MIMEDX Announces Chief Financial Officer Transition

Company applauds the Office of Inspector General's (“OIG”) recommendation for the Centers for Medicare and Medicaid Services (“CMS”) to quickly address issues associated with Average Sales Price (“ASP”) reporting requirements for skin substitute products Company applauds the Office of Inspector General's (“OIG”) recommendation for the Centers for Medicare and Medicaid Services (“CMS”) to quickly address issues associated with Average Sales Price (“ASP”) reporting requirements for skin substitute products

MIMEDX Comments on Recent Data Brief Published by Office of Inspector General

MiMedx Group, Inc. (NASDAQ:MDXG ) Q4 2022 Results Conference Call February 28, 2023 5:00 PM ET Company Participants Matt Notarianni - Head, IR Joe Capper - CEO Pete Carlson - CFO Conference Call Participants Anthony Petrone - Mizuho Group Carl Byrnes - Northland Capital Markets Swayampakula Ramakanth - H.C. Wainwright John Vandermosten - Zacks Operator Good afternoon, and thank you for standing by.

MiMedx Group, Inc. (MDXG) Q4 2022 Earnings Call Transcript

Reports Highest Quarterly Net Sales Since the Fourth Quarter of 2019

MIMEDX Announces Fourth Quarter and Full Year 2022 Operating and Financial Results

Highly experienced and accomplished three-time healthcare CEO with a proven track record of substantial value creation to lead MIMEDX

MIMEDX Appoints Joseph H. Capper as Chief Executive Officer and Director

Fourth quarter and full year 2022 net sales expected in the ranges of $73 million to $76 million and $266 million to $269 million, respectively

MIMEDX Confirms Fourth Quarter and Full Year 2022 Net Sales Expectations, Comments on Evolving Medicare Reimbursement Landscape and Provides Corporate Updates

MIMEDX aligns with a leading distributor of wound care products in Japan to capitalize on first-mover advantage for EPIFIX

MIMEDX Announces Commercial Launch of EPIFIX® in Japan with Exclusive Distribution Agreement with GUNZE MEDICAL LIMITED

MiMedx Group, Inc. (NASDAQ:MDXG ) Q3 2022 Earnings Conference Call November 2, 2022 5:00 PM ET Company Participants Matt Notarianni – Head-Investor Relations Todd Newton – Interim Chief Executive Officer Pete Carlson – Chief Financial Officer Rohit Kashyap – President-Wound and Surgical Robert Stein – President-Regenerative Medicine Conference Call Participants Anthony Petrone – Mizuho Group RK – H.C. Wainwright Carl Byrnes – Northland Capital John Vandermosten – Zacks Operator Good afternoon and thank you for standing by.

MiMedx Group, Inc. (MDXG) Q3 2022 Earnings Call Transcript

Third Quarter Net Sales of $67.7 Million Reflect Growth of 7.3%

MIMEDX Announces Third Quarter 2022 Operating and Financial Results

New Product Enables Company to Target Additional Surgical Procedures and Deepen Market Penetration in the Growing $1B Surgical Recovery Market

MIMEDX Announces Launch of AMNIOEFFECT™

Provides Favorable Access to a New $500 Million Market for the Treatment of Refractory Diabetic and Venous Ulcers for EPIFIX – the First and Only Amniotic Tissue Product Approved for Use in Japan

MIMEDX EPIFIX® Receives Reimbursement Approval in Japan

The Cato T. Laurencin Regenerative Engineering Founders' Award Promotes Advancement of Scientific Leadership and Research in the Field of Regenerative Engineering

Regenerative Engineering Society Establishes Award in Honor of MIMEDX Board Member, Dr. Cato T. Laurencin

MARIETTA, Ga., Aug. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management will present at the Canaccord Genuity 42nd Annual Growth Conference in Boston on Wednesday, August 10, 2022 at 3:00 p.m. Eastern Time. Institutional investors interested in a meeting with senior management may contact their Canaccord Genuity representative.

MIMEDX to Present at the Canaccord Genuity 42nd Annual Growth Conference

MiMedx Group, Inc. (NASDAQ:MDXG ) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Jack Howarth – Senior Vice President-Investor Relations Tim Wright – Chief Executive Officer Pete Carlson – Chief Financial Officer Rohit Kashyap – President Wound Care and Surgical Robert Stein – President, Regenerative Medicine and Biologics Innovation Conference Call Participants Anthony Petrone – Mizuho Group RK – H.C. Wainwright Carl Byrnes – Northland Capital Markets John Vandermosten – Zacks Operator Greetings, and welcome to the MiMedx Group Second Quarter 2022 Operational and Financial Results Conference Call.

MiMedx Group, Inc.'s (MDXG) CEO Tim Wright on Q2 2022 Results - Earnings Call Transcript

MARIETTA, Ga., July 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the second quarter ended June 30, 2022, after the market close on Tuesday, August 2, 2022. The MIMEDX senior management team will host a webcast and conference call to review its results on Wednesday, August 3, 2022, beginning at 8:30 a.m. Eastern Time.

MIMEDX to Host Second Quarter 2022 Operating and Financial Results Conference Call on August 3

Proven Biotech Executive Brings Versatile Leadership Experience

MIMEDX Welcomes Kate Surdez as Chief Human Resources Officer

Image Analysis Group to Provide Imaging Strategy and Advanced Imaging Analytics in Support of MIMEDX's Knee Osteoarthritis Clinical Trial Program

MIMEDX Engages Nordic Bioscience Clinical Development A/S to Propel Registrational Trials of Placental Biologic Injectable for Knee Osteoarthritis

Notes that a Majority of the Non-Affiliated, Non-Institutional Shares Voted Against the Re-Election of Incumbent Directors, and Against Approval of Executive Compensation Demands Leadership Immediately Address Massive Divergence Between the Share Price and Underlying Value Vows to Continue Its Efforts to Hold MiMedx Leadership Accountable BATON ROUGE, La. , June 14, 2022 /PRNewswire/ -- Prescience Point Capital Management LLC ("Prescience Point"), a research-focused, catalyst-driven investment firm that beneficially owns approximately 6.7% of the outstanding common stock of MiMedx Group, Inc. ("MDXG" or the "Company") (NASDAQ: MDXG), today issued an open letter to shareholders commenting on the results of the Company's annual meeting of shareholders, held on June 7, 2022: Dear Fellow MiMedx Shareholders: MiMedx has attempted to put a positive spin on the voting results of its recent annual meeting, but a more detailed and objective analysis of the results paints a far different picture and reflects widespread discontent within the Company's shareholder base.

Prescience Point Capital Management Says MiMedx Shareholders Have Spoken: Voiced Their Desire For Change

Dr. Phyllis Gardner and James L. Bierman Reelected to Board of Directors

MIMEDX Shareholders Vote to Approve All Proposals at the 2022 Annual Meeting

Believes That a Massive Number of Shares Voted Against the Re-Election of Incumbent Directors and Against Approval of Executive Compensation BATON ROUGE, La. , June 7, 2022 /PRNewswire/ -- Prescience Point Capital Management LLC ("Prescience Point"), a research-focused, catalyst-driven investment firm that beneficially owns approximately 6.7% of the outstanding common stock of MiMedx Group, Inc. ("MDXG" or the "Company") (NASDAQ: MDXG), has issued a statement, calling upon the Company to report the preliminary results of its annual meeting of shareholders, held earlier today.

Prescience Point Capital Management Calls On MiMedx Group to Immediately Release Preliminary Voting Results of its Annual Meeting

Deadline to Pre-Register is 9:00 a.m. Eastern Time on June 6, 2022

MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2022 Annual Meeting of Shareholders

Company Highlights Factually Accurate Information Already Provided

MIMEDX Addresses Presentation by Prescience Point

Urges Shareholders to Vote “FOR” MIMEDX's Highly Qualified and Independent Directors – James L. Bierman and Phyllis Gardner, M.D. on the WHITE Proxy Card Today

News for MiMedx Group Stock (MDXG)